Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics develops next-generation therapies for severe autoimmune and inflammatory diseases as a clinical-stage biotechnology company. Its updates center on claseprubart, an investigational monoclonal antibody engineered to selectively inhibit the active form of C1s in the classical complement pathway, with programs in chronic inflammatory demyelinating polyneuropathy, generalized myasthenia gravis and multifocal motor neuropathy.
Recurring company news also covers FDA interactions and designations, clinical and preclinical program updates, financial results, public equity offerings, pre-funded warrants, and inducement equity grants under Nasdaq rules. Additional disclosures address DNTH212 and the company’s stated focus on rheumatology indications such as Sjögren’s disease, systemic lupus erythematosus and dermatomyositis.
Dianthus Therapeutics (Nasdaq: DNTH) announced an early GO decision for the Phase 3 CAPTIVATE CIDP trial after achieving 20 confirmed responders with fewer than 40 participants completing open-label Part A. The company reported $514.4 million cash as of December 31, 2025, runway into 2028, full-year R&D of $145.6 million, and a 2025 net loss of $162.3 million. Key development timelines: gMG Phase 3 start mid-2026 (top-line 2H'28), MMN Phase 2 top-line 2H'26, and DNTH212 Phase 1 healthy volunteer data expected 2H'26.
Dianthus Therapeutics (Nasdaq: DNTH) announced an early GO decision in the Phase 3 CAPTIVATE trial of claseprubart for CIDP after an interim responder analysis met the predefined GO criterion.
The company reached 20 confirmed responders early, confirmed by an independent DSMB with no related serious infections or related serious adverse events. Planned updates include keeping the 300mg/2mL S.C. Q2W dose, seeking to remove the 600mg/4mL arm from Part B, reducing Part A enrollment to up to 256 patients (randomize 128 in Part B), and providing Part B top-line guidance by end of 2026.
Dianthus Therapeutics (Nasdaq: DNTH) will host a conference call and webcast on March 9, 2026 at 8:00 a.m. ET to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.
Live access is available by phone with pre-registration and via the investor webcast at https://investor.dianthustx.com/. A replay will be posted following the call.
Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on March 2, 2026 to three newly hired, non-executive employees.
The awards are non-qualified options for an aggregate of 26,000 shares, 10-year term, exercise price $55.26, vesting 25% after one year then monthly over 36 months.
Dianthus Therapeutics (Nasdaq: DNTH) will participate in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO, will join an analyst-led fireside chat on March 3, 2026 at 1:50 pm ET and hold one-on-one investor meetings.
A webcast will be available under News and Events in the Investors section of the company's website.
Dianthus Therapeutics (Nasdaq: DNTH) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City.
CEO Marino Garcia will join an analyst-led fireside chat on Thursday, February 12, 2026 at 10:00 am EST and hold one-on-one investor meetings. A webcast will be available under "News and Events" in the Investors section of the Dianthus Therapeutics website.
Dianthus Therapeutics (Nasdaq: DNTH) announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Marino Garcia will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 pm EST and will hold one-on-one investor meetings.
A webcast of the presentation will be available in the company’s Investors section under “News and Events.” The announcement highlights investor access opportunities but does not provide financial or clinical data in this release.
Dianthus Therapeutics (Nasdaq: DNTH) and Leads Biolabs announced dosing of the first subject in the Phase 1 trial of LBL-047 (DNTH212) on Dec 23, 2025. The two-part, randomized, double-blind, placebo-controlled, single-ascending-dose study will evaluate safety, tolerability and PK/PD in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B).
The bifunctional fusion protein targets pDC BDCA2 to reduce Type 1 interferon and inhibits BAFF/APRIL to suppress B cells. Leads and Dianthus formed an exclusive global partnership on Oct 16, 2025, with total potential deal value up to $1 billion; Dianthus holds rights outside Greater China. Top-line healthy-volunteer results are anticipated in 2H’26, and Dianthus will update indication prioritization in 1H’26.
Dianthus Therapeutics (Nasdaq: DNTH) will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. Marino Garcia, CEO, will join a fireside chat on December 2, 2025 at 2:35 p.m. ET and will hold one-on-one investor meetings.
A live webcast of the presentation may be accessed via the News and Events page in the Investors section of the Dianthus Therapeutics website.
Dianthus Therapeutics (Nasdaq: DNTH) reported Q3 2025 results and business updates highlighting positive clinical progress for claseprubart (DNTH103), the in-licensing of DNTH212, and a strengthened cash position. Key clinical developments include statistically significant Phase 2 MaGic gMG results at Week 13, AANEM data supporting potential 300mg/2mL Q4W dosing, planned Phase 3 gMG initiation in 2026 with two dose arms, accelerated CIDP Phase 3 interim responder analysis to Q2 2026, and ongoing MMN Phase 2 with top-line in 2H’26. Financial highlights: estimated adjusted cash of ~$525M (runway into 2028), R&D of $32.5M in Q3, and net loss of $36.8M (Q3 2025).